Drug intelligence / Profile preview

HH101

Development stage: Preclinical
Lead developer: Hedgehog Technology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

HH101 is a monoclonal antibody being developed by Hedgehog Technology (Hedgehog, Inc.) for the treatment of solid cancers. It specifically targets the Smoothened (SMO) receptor, a transmembrane protein that is a key component of the Hedgehog signaling pathway. By binding to SMO, HH101 aims to inhibit aberrant Hedgehog signaling, which is a known driver of cell proliferation, survival, and metastasis in various solid malignancies. The drug is currently in the early discovery (Hit) stage of preclinical development.

Targets

SMO (Smoothened)

Beyond the preview

Go deeper on HH101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HH101.

Explore the full profile